In the last 20 years or so, the remission rate of pediatric acute non-lymphoblastic leukemia has been increasing from 20% to 50-60% due to the gradual understanding of the cell morphology, immunophenotype, cytogenetics and even molecular biology of pediatric acute non-lymphoblastic leukemia, the improvement and innovation of treatment strategies and methods, the enhancement of chemotherapy intensity and the development of bone marrow transplantation. -60%. However, the efficacy of pediatric acute NHL is far less than that of pediatric acute NHL. In the last 20 years or so, the treatment of pediatric acute NHL has improved the remission rate and the long-term disease-free survival rate has also improved significantly. Chemotherapy for acute NHL in children is divided into two phases: 1. induction of remission therapy 2. post-remission therapy.